FDA
EMA
MHRA
PMDA
Health Canada

Clinical

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Competitive

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Asset / Drug

NIDDK

Drug and asset intelligence for NIDDK with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 1
Stage: Development stage unavailable

Sponsor company

biotech companies focused on endocrinology →

Recent signals(2)

ClinicalJuly 26, 2026

Blood Sampling Study for Sickle Cell Disease Research Initiated by NIDDK

A study has been launched to collect blood samples from individuals with unique red blood cell features related to sickle cell disease.

ClinicalJuly 9, 2026

NIDDK Launches Genetic Study on Insulin Resistance and Diabetes

The NIDDK is conducting a genetic study to explore insulin resistance and diabetes by comparing affected patients to healthy individuals.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

— NIDDK

July 9, 2026 · N/A

Indications

Diabetes →

Sickle Cell Disease →

Therapeutic areas

Diabetes →

Endocrinology →

Endocrinology · Diabetes →

Hematology →

Sickle Cell Disease →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.